Tumor adaptation to treatment with EGFR antagonists thus involves metabolic reprogramming in HNSCC cells, enabling them to survive in vivo despite an impaired functional vasculature and hypoxic microenvironment. The gene discussed is EGFR; the disease is neoplasm.